Company Overview of Prosensa Holding N.V.
Prosensa Holding N.V., a biotechnology company, engages in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders. The company’s products focus on the treatment of neuromuscular and neurodegenerative disorders, including duchenne muscular dystrophy (DMD), myotonic dystrophy, and huntington’s diseases. It develops drisapersen, which is in Phase III studies to restore dystrophin expression and enhancing muscle condition; PRO044 that is in Phase I/II studies to address a separate sub-population of DMD patients; and PRO045, PRO053, PRO052, and PRO055 to address other distinct sub-populations of DMD patients. The company also develops PRO1...
J.H. Oortweg 21
Leiden, 2333 CH
Founded in 1997
Key Executives for Prosensa Holding N.V.
Prosensa Holding N.V. does not have any Key Executives recorded.
Prosensa Holding N.V. Key Developments
Prosensa Holding N.V., Special/Extraordinary Shareholders Meeting, Jan 13, 2015
Dec 9 14
Prosensa Holding N.V., Special/Extraordinary Shareholders Meeting, Jan 13, 2015., at 14:00 Central European Standard Time. Location: The offices of company, J.H. Oortweg 21. Agenda: To consider the regarding the recommended tender offer of BioMarin Falcons B.V. and one or more of its affiliates for all the outstanding ordinary shares with a nominal value of €0.01 in the share capital of the company, in exchange for (i) $17.75 per share, net to the seller in cash, without interest and less any applicable withholding taxes, plus (ii) one non-transferrable contingent value right, which represents the contractual right to receive cash payments of up to $4.14 per Share in aggregate, without interest and less any applicable withholding taxes, upon the achievement of certain product approval milestones with respect to the commercialization of drisapersen within certain time periods; to consider the discharge of the current managing Directors; to consider the appointment and reappointment of the Directors; to consider the discharge of the resigning Supervisory Directors; to consider the appointment and reappointment of the Directors; and to consider other issues.
BioMarin Pharmaceutical Inc., Prosensa Holding N.V. - M&A Call
Nov 24 14
To discuss the definitive agreement in which BioMarin Pharmaceutical Inc. will offer to purchase all of the outstanding ordinary shares of Prosensa Holding N.V
Prosensa Holding N.V. Reports Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Cash and Cash Equivalents Guidance for December 31, 2014
Nov 17 14
Prosensa Holding N.V. reported consolidated unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported operating loss was €10.522 million compared with €4.282 million for the same period last year. Net loss was €10.649 million or €0.29 basic and diluted per share compared with €4.293 million or €0.12 basic and diluted per share for the same period last year.
For the nine months, the company reported total revenue was €14.755 million compared with €6.763 million for the same period last year. Operating loss was €11.166 million compared with €12.334 million for the same period last year. Net loss was €11.320 million or €0.31 basic and diluted per share compared with €12.452 million or €0.40 basic and diluted per share for the same period last year.
The company expect that cash and cash equivalents as of December 31, 2014 will range from 52 million to 54 million. This guidance does not account for the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to the company's capital structure, including future securities offerings.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 24, 2014
August 11, 2014